

Kerecis® Omega3 SurgiClose™ Micro

Fragmented, intact
fish-skin graft

kerecis®

- Designed to fill and adhere to uneven and complex wound surfaces
- Offers more surface area coverage than non-fragmented grafts
- Provides an optimal environment for the body's own cells²
- Excellent handling for application with minimal wastage of the product



Kerecis Omega3 Technology

Kerecis Omega3 fish-skin products are homologous to human skin¹ and used to support tissue regeneration and repair.² Kerecis Omega3 fish-skin products are FDA approved for multiple clinical applications.

Because there is no risk of a viral-disease transfer from Atlantic cod to humans, the fish skin needs only mild processing, resulting in the preservation of the fish skin's natural structure and elements, including Omega3 fatty acids.^{3,4}

When grafted onto damaged human tissue, such as a burn or a wound, the fish skin recruits the body's own cells, supporting the ability to regenerate.²

The superior clinical and economic performance of Kerecis Omega3 fish skin has been demonstrated in multiple blinded, randomized, controlled clinical trials^{4,5,6} and numerous other clinical studies.⁷⁻¹⁵

Since there are no known religious or cultural barriers associated with Kerecis Omega3 products, they can help diverse communities.

Pre-debridement



SurgiClose Micro Applied



SurgiClose Cover



Wound Healed



INTENDED USE


Kerecis® Omega3 SurgiClose™ is indicated for the management of wounds including:

- Partial and full thickness wounds
- Pressure ulcers
- Chronic vascular ulcers
- Diabetic ulcers
- Trauma wounds (abrasions, lacerations, second-degree burns, skin tears)
- Surgical wounds (donor site/grfts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence)
- Draining wounds

An FDA 510(k) approved medical device for managing wounds. Not subject to the May 31, 2021, FDA guidance on human cells, tissues and cellular and tissue-based products (HCT/PS).

Accelerated healing compared to afterbirth products⁵

The Kerecis® Omega3 fish skin's thickness and porous microstructure demonstrated significantly more ($p < 0.0001$) three-dimensional cell ingrowth than human amnion/chorion membranes and faster healing.⁵



Kerecis Omega3 SurgiClose Micro

| Catalog # Box of 10 | Catalog # Single Unit | Product Size | Coverage (cm ² / unit) |
|------------------------|--------------------------|--------------------|--------------------------------------|
| 50205P02D2D | 50205P02D0D | 19 cm ² | 19 |
| 50205P04D2D | 50205P04D0D | 38 cm ² | 38 |

References:

1) Magnusson, S., Baldursson, B. T., Kjartansson, H., Rolfsson, O. & Sigurjonsson, G. F. Regenerative and Antibacterial Properties of Acellular Fish Skin Grafts and Human Amnion/Chorion Membrane: Implications for Tissue Preservation in Combat Casualty Care. *Mil. Med.* 182, 383–388 (2017). 2) Magnusson, S. et al. Decellularized fish skin: characteristics that support tissue repair. *Laeknabladid* 101, 567–573 (2015). 3) Rakers, S. et al. 'Fish matters': the relevance of fish skin biology to investigative dermatology. *Exp. Dermatol.* 19, 313–324 (2010). 4) Baldursson, B. T. et al. Healing rate and autoimmune safety of full-thickness wounds treated with fish skin acellular dermal matrix versus porcine small-intestine submucosa: a noninferiority study. *Int. J. Low. Extrem. Wounds* 14, (2015). 5) Kirsner, R. S. et al. Double-Blind, Prospective, Randomized Clinical Trial on 170 Acute Wounds Shows Significantly Faster Healing Rate with Intact Fish Skin Compared to Human Amniotic Membrane. *Natl. Am. Podiatr. Med. Assoc. Annu. Sci. Meet.* (2018). 6) Lullove E. J. et al. A multicenter, blinded, randomized controlled clinical trial evaluating the effect of Omega-3-rich fish skin in the treatment of chronic, nonresponsive diabetic foot ulcers. *Wounds*. Published online April 15, 2021. 8) Stone R 2nd, Saathoff EC, Larson DA, et al. Accelerated Wound Closure of Deep Partial Thickness Burns with Acellular Fish Skin Graft. *Int J Mol Sci.* 2021;22(4):1590. 9) Yang CK, Polanco TO, Lantis JC 2nd. A Prospective, Postmarket, Compassionate Clinical Evaluation of a Novel Acellular Fish-skin Graft Which Contains Omega-3 Fatty Acids for the Closure of Hard-to-heal Lower Extremity Chronic Ulcers. *Wounds*. 2016 Apr;28(4):112-8. PMID: 27071138. 10) T. T. Trinh, F. Dünschede, C.-F. Vahl & B. Dorweiler. Marine Omega3 Wound Matrix for the Treatment of Complicated Wounds. *Phlebologie* 45, 93–98 (2016). 11) Dorweiler, B. et al. Die marine Omega-3-Wundmatrix zur Behandlung komplizierter Wunden. *Gefässchirurgie* 22, 558–567 (2017). 12) Woodrow, T., Chant, T. & Chant, H. Treatment of diabetic foot wounds with acellular fish skin graft rich in omega-3: a prospective evaluation. *J. Wound Care* 28, 76–80 (2019). 13) Sitje, T. S., Grandahl, E. C. & Sørensen, J. A. Clinical innovation: fish-derived wound product for cutaneous wounds. *Wounds Int.* 2018 9, 44–50 (2018). 14) Patel, M. & Lantis II, J. C. Fish skin acellular dermal matrix: potential in the treatment of chronic wounds. *Chronic Wound Care Manag. Res.* 6, 59–70 (2019). 15) Sibbald R., Goodman L., Woo K. et al (2011) Special considerations in wound bed preparation 2011: An update. *Adv Skin Wound Care.* 24(9):415-36.

kerecis®

OUR VISION
To extend human life
by supporting the body's
own ability to regenerate

FDA approved, U.S. and international
patents and trademarks granted and
pending.

KERECIS
2300 Clarendon Boulevard
Suite 1210
Arlington, Virginia 22201
Phone: (703) 287-8752
Email: info@kerecis.com
www.kerecis.com